New cancer pill tested in humans – but trial halted early
NCT ID NCT05605119
First seen Apr 18, 2026 · Last updated Jun 19, 2026 · Updated 16 times
Summary
This early-stage trial tested an oral drug called AUR105 in 17 adults with advanced solid tumors or lymphomas that had not responded to prior treatments. The study aimed to find a safe dose and check how the drug moves through the body. However, the trial was terminated, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ALL India Institute of medical Scieneces
New Delhi, New Delhi, 110029, India
-
All India Institute of Medical Sciences
Bhubaneswar, Odisha, 751019, India
-
HCG City Cancer Center
Vijayawada, Andhra Pradesh, 520002, India
-
IMS&SUM Hospital
Bhubaneswar, Bhubaneswar, 751003, India
-
Kailash Cancer Hospital and Research Centre
Vadodara, Gujarat, 391760, India
-
Krupamayi Hospital
Aurangabad, Maharashtra, 431001, India
-
Moraya Multi-Speciality Hospital
Pune, Maharasthra, 411033, India
-
Omega Hospitals
Visakhapatnam, Andhra Pradesh, 530040, India
-
Sparsh Hospital and Critical Care
Bhubaneswar, Odisha, 751007, India
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AUR105 (oral drug)
What this could lead to
If successful, this could point toward a new treatment option for advanced cancers that have stopped responding to other therapies.
What could go wrong
This is a very early, small Phase 1 trial (only 17 participants) that was terminated, so results are limited. The drug may not prove effective or safe in larger studies.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.